A recent study revealed that α7 nAChR acts via an activation of adenylyl cyclase 6 and a lipid raft-mediated endocytosis of TLR4 in a COPD mouse model and proposed the use of α7 agonists as a novel approach for COPD treatment [45]. Here, CHRNA7 is linked to chronic obstructive pulmonary disease.